Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report) insider David P. Hochman bought 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 24th. The stock was purchased at an average price of $4.91 per share, for a total transaction of $12,275.00. Following the acquisition, the insider now directly owns 570,498 shares in the company, valued at $2,801,145.18. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Orchestra BioMed Stock Up 1.7 %
OBIO stock opened at $4.69 on Thursday. The business has a fifty day moving average of $6.28 and a 200-day moving average of $6.12. The company has a market cap of $177.42 million, a P/E ratio of -3.17 and a beta of 0.44. Orchestra BioMed Holdings, Inc. has a twelve month low of $4.22 and a twelve month high of $11.69.
Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.04). Orchestra BioMed had a negative return on equity of 89.28% and a negative net margin of 2,673.26%. The business had revenue of $0.78 million for the quarter, compared to analyst estimates of $1.04 million. As a group, equities research analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.67 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Orchestra BioMed
Wall Street Analyst Weigh In
Several research analysts have commented on the company. Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a research report on Wednesday, June 12th. HC Wainwright started coverage on shares of Orchestra BioMed in a research report on Thursday, August 22nd. They issued a “buy” rating and a $14.00 price target for the company. Finally, B. Riley began coverage on Orchestra BioMed in a research report on Thursday, July 25th. They set a “buy” rating and a $15.00 target price for the company.
View Our Latest Report on OBIO
About Orchestra BioMed
Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
See Also
- Five stocks we like better than Orchestra BioMed
- Ride Out The Recession With These Dividend KingsĀ
- Are Crypto Stocks Still Worth Watching as Bitcoin Consolidates?
- The 3 Best Blue-Chip Stocks to Buy Now
- How to Invest in Bonds: A Beginner’s Guide
- Health Care Stocks Explained: Why You Might Want to Invest
- Can Gen-AI Drive Coursera Stock to Double-Bagger Returns?
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.